Engineering t cell receptors

Sheena N. Smith (Inventor), David M Kranz (Inventor)

Research output: Patent

Abstract

The use of model T cell receptors (TCRs) as scaffolds for in vitro engineering of novel specificities is provided. TCRs with de novo binding to a specific peptide-major histocompatibility complex (MHC) product can be isolated by: 1) mutagenizing a T cell receptor protein coding sequence to generate a variegated population of mutants (a library), 2) selection of the library of TCR mutants with the specific peptide-MHC, using a process of directed evolution and a “display” methodology (e.g., yeast, phage, mammalian cell) and the peptide-MHC ligand. The process can be repeated to identify TCR variants with improved affinity for the selecting peptide-MHC ligand.
Original languageEnglish (US)
U.S. patent number11384133
Filing date4/13/18
StatePublished - Jul 12 2022

Fingerprint

Dive into the research topics of 'Engineering t cell receptors'. Together they form a unique fingerprint.

Cite this